This week in medicine 1. Optogenetics wins the Nobel Prize! It goes to Karl Deisseroth, Peter Hegemann and Georg Nagel. 2. Full phase 3 results published for Lilly’s triple-G, retatrutide: ~25% mean weight loss. 3. ARPA-H plans to cut drug development from 10+ years to <4 years: with phaseless trials, adaptive platforms, digital twins and AI agents. 4. Pfizer's trispecific antibody works (in a phase 2 trial) in atopic dermatitis - it blocks IL-4, IL-13 and TSLP. 5. Dana-Farber researchers develop a new way to drug undruggable GPCRs, with GTACs: bispecific antibodies that use the transferrin receptor to drag GPCRs into lysosomes. 6. FDA approves the Autus Size-Adjustable Valve, for patients with congenital pulmonary valve disease - the first heart valve that grows with a child. 7. The first treatment for the rare genetic disease, MCT8 deficiency, is FDA-approved - a thyroid-hormone analogue that reduces peripheral thyrotoxicosis. 8. Both of Kodiak’s next-gen antibodies work in phase 3 trials for wet age-related macular degeneration - the long-acting anti-VEGF antibody–biopolymer conjugate and the bispecific VEGF-trap/anti-IL6 therapy. 9. Roche's all-oral combo of giredestrant (SERD) + everolimus (mTOR inhibitor) targets both ER and PI3K–AKT–mTOR resistance, cutting progression in ESR1-mutant breast cancer. 10. Lilly’s EloraTZP, an amylin agonist-tirzepatide combination, beats tirzepatide alone in a phase 2 diabetes trial (with increased risk of adverse events).